department

Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access

therapeutic area

Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease

location & type

Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →

when

Latest
Archive

by source

All Sources
Sources Page

by activity

Most Active
Biggest Pipelines
Recently Active

hiring

Companies Hiring Now
Big Pharma Roles
All Companies →

Drugs & Pipeline

intelligence

Drugs
Patent Cliff

research

Publications
Topics

window

Next 90 Days
All (incl. Past)

by type

PDUFAs
Approvals
Earnings
Readouts

Sign In Subscribe

pharmadog

fetch the data · sniff the signal

Discover

Calendar
Drugs
Companies
News

Hubs

Topics
Jobs
Patent cliff
Publications

Tools

Compare
Search
Bookmarks

Trust

About
Sources
Contact

Legal

Privacy
Terms
Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

home
jobs
news
cal
search

Hansa Biopharma AB · pharmadog

PUBLIC COMPANY

Hansa Biopharma AB

updated 1mo ago

community read0 votes

pipeline

2

marketed

0

phase 3

0

catalysts ytd

0

approvals ytd

0

recalls ytd

0

Pipeline(2)

pipeline depth2 products

1Phase 11pre_registration

Guillain-Barre Syndrome

pre_registration

Kidney Transplant Rejection

Upcoming

no upcoming catalysts on record

Recent(90d)

nothing in the last 90 days

view all catalysts →

🐶 Hiring Signal

No open roles indexed yet — view Hansa Biopharma AB jobs →

News

no news has mentioned this company yet

identifiers

source

globaldata

top tags

mentioned in

0news items

entity-linker matched

comments(0)

5-min edit window · permanent after that

sign in to leave a comment · permanent archive after 5 minutes

no comments yet — first sniff?

Active trials

phase2Imlifidase Prior to Kidney Transplant in Highly Sensitised Childrenrecruitingn=10
phase3A Long-term Follow-up Trial of Patients Previously Treated With Imlifidase Prior to Kidney Transplantation and a Non-comparative Transplanted Patient Grouprecruitingn=150
phase3Efficacy and Safety in Imlifidase Desensitized Kidney Tx Patients, Including Two Non-Comparative Reference Cohortsactive not recruitingn=225
phase3A Study With Imlifidase in Anti-GBM Diseaseterminatedn=50
—Survival and Dialysis Independency in Highly Sensitized Patients After Desensitization With Imlifidase and Tx of Kidneysactive not recruitingn=64
phase2A Study to Investigate DSA Rebound in Patients Treated With Imlifidase Prior to Transplantationterminatedn=3
phase3Renal Function in Highly Sensitized Patients 1 Year After Desensitization With Imlifidase Prior to DD Kidney Txcompletedn=64
—An Long-term Follow-up Trial of Kidney Tx Patients Treated With Imlifidase or PE After an AMRterminatedn=18

more trials →